Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge

Cancer Research

Volumn 75, Issue 1, 2015, Pages 5-10

  Makkouk, Amani ^a   Weiner, George J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BLINATUMOMAB; CATUMAXOMAB; GLYCOPROTEIN; GLYCOPROTEIN 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL PROLIFERATION; CELL THERAPY; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOMA; MELANOMA; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; UTERINE CERVIX CARCINOMA; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANTIGENS, NEOPLASM; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84920545991     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2538     Document Type: Review

References (37)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
3. Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol 2012;3:3.
4. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1-14.
5. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009;229:126-44.
6. Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol 2013;3:231.
7. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
8. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.
9. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012;1:28-37.
10. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011;29:4828-36.
11. May C, Sapra P, Gerber H. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol 2012;84:1105-12.
12. Mathur R, Weiner GJ. Picking the optimal target for antibody-drug conjugates. Am Soc Clin Oncol Educ Book 2013.doi: 10.1200/EdBook.
13. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology 2012;1:306-15.
14. Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 2005;17:187-94.
15. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86:1159-66.
16. Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Trans Immunol 2014;3:e16.
17. Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without Gvhd in children and adults with relapsed, refractory ALL. Poster Pres Am Soc Hematol 2013;122:67.
18. Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, et al. Antitumor vaccination: Where we stand. Haematologica 2000;85:1172-206.
19. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011;30:150-82.
20. Browning MJ. Antigen presenting cell/tumor cell fusion vaccines for cancer immunotherapy. Hum Vaccin Immunother 2013;9:1545-8.
21. Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 2011;17:343-50.
22. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27.
23. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787-94.
24. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77.
25. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
26. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012;1:1111-34.
27. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: FDA-approved toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:894-907.
28. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial watch: immunostimulatory cytokines. Oncoimmunology 2012;1:493-506.
29. Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J 2010;16:311-7.
30. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46.
31. Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 2011;112:1969-77.
32. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013;13:5.
33. Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Cancer Immunotherapy Highlights from the 2014 ASCO Meeting. Cancer Immunol Res 2014;2:714-9.
34. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
35. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
36. Ludgate CM. Optimizing cancer treatments to induce an acute immune response: radiation abscopal effects, PAMPs, and DAMPs. Clin Cancer Res 2012;18:4522-5.
37. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010;28:4324-32.